Ultragenyx Pharmaceutical Inc
RARE31.035USD
-10.405-25.11%
收盘 07/10, 16:00（美东）报价延迟15分钟
2.91B总市值
亏损市盈率 TTM
关于 Ultragenyx Pharmaceutical Inc 公司
Ultragenyx Pharmaceutical Inc. 是一家生物制药公司。该公司专注于识别、收购、开发和商业化用于治疗严重罕见和极罕见遗传病的新产品。其疗法和临床阶段产品线包括四类产品：生物制剂、小分子、AAV 基因治疗和核酸候选产品。该公司的四种获批候选产品包括用于治疗 X 连锁低磷血症 (XLH) 和肿瘤诱发性骨软化症 (TIO) 的 Crysvita (burosumab)、用于治疗粘多糖贮积症 VII (MPSVII) 或 Sly 综合征的 Mepsevii (vestronidase alfa)、用于治疗长链脂肪酸氧化障碍 (LC-FAOD) 的 Dojorvi (triheptanoin) 和用于治疗纯合家族性高胆固醇血症 (HoFH) 的 Evkeeza (evinacumab)。其临床候选产品包括DTX401、DTX301和UX701。DTX401用于治疗Ia型糖原累积病。
公司简介
公司代码RARE
公司名称Ultragenyx Pharmaceutical Inc
上市日期Jan 31, 2014
成立日期2011
CEODr. Emil D. Kakkis, M.D., Ph.D.
员工数量1294
证券类型Ordinary Share
年结日Jan 31
公司地址60 Leveroni Ct
城市NOVATO
上市交易所NASDAQ Global Select Consolidated
国家United States of America
邮编94949
电话14154838800
网址https://www.ultragenyx.com/
公司代码RARE
上市日期Jan 31, 2014
成立日期2011
公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
Dr. Amrit Ray, M.D.
Dr. Amrit Ray, M.D.
Independent Director
Independent Director
18.02K
+46.74%
Mr. Howard Horn
Mr. Howard Horn
Chief Financial Officer, Executive Vice President, Corporate Strategy
Chief Financial Officer, Executive Vice President, Corporate Strategy
15.69K
-83.00%
Mr. John R. Pinion, II
Mr. John R. Pinion, II
Chief Quality Officer, Executive Vice President - Translational Sciences
Chief Quality Officer, Executive Vice President - Translational Sciences
--
--
Dr. Deborah L. Dunsire, M.D.
Dr. Deborah L. Dunsire, M.D.
Independent Director
Independent Director
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Dr. Emil D. Kakkis, M.D., Ph.D.
Dr. Emil D. Kakkis, M.D., Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.69M
-1.17%
Mr. Dennis Karl Huang
Mr. Dennis Karl Huang
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
Executive Vice President, Chief Technical Operations Officer, Gene Therapy Operations
107.20K
+41.78%
Mr. Erik Harris
Mr. Erik Harris
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
41.99K
+83.47%
Mr. Daniel G. Welch
Mr. Daniel G. Welch
Independent Chairman of the Board
Independent Chairman of the Board
27.34K
+26.57%
Mr. Michael A. Narachi
Mr. Michael A. Narachi
Independent Director
Independent Director
27.34K
+26.57%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
20.59K
+38.64%
收入明细
单位: USD更新时间: 7月6日 周日
单位: USD更新时间: 7月6日 周日
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
业务USD
名称
营收
占比
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
地区USD
名称
营收
占比
North America
57.79M
41.49%
Latin America
54.89M
39.40%
Europe
23.33M
16.75%
Japan
3.29M
2.36%
业务
地区
业务USD
名称
营收
占比
Crysvita
55.08M
39.54%
Crysvita royalty revenue
47.78M
34.31%
Dojolvi
17.01M
12.21%
Evkeeza
11.03M
7.92%
Mepsevii
8.39M
6.02%
股东统计
更新时间: 5月17日 周六
更新时间: 5月17日 周六
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
持股股东
持股股东
占比
The Vanguard Group, Inc.
10.55%
BlackRock Institutional Trust Company, N.A.
5.20%
Sands Capital Management, LLC
4.40%
T. Rowe Price Associates, Inc.
3.32%
Kakkis (Emil D)
2.85%
Other
73.68%
股东类型
持股股东
占比
Investment Advisor/Hedge Fund
44.96%
Investment Advisor
27.79%
Hedge Fund
21.16%
Individual Investor
3.56%
Research Firm
1.72%
Sovereign Wealth Fund
1.02%
Private Equity
0.70%
Pension Fund
0.65%
Bank and Trust
0.28%
机构持股
更新时间: 7月1日 周二
更新时间: 7月1日 周二
报告期
机构数
持股数
持股占比
持股变动
2025Q2
627
96.81M
102.40%
-2.03M
2025Q1
652
96.83M
102.45%
-3.19M
2024Q4
645
94.29M
102.32%
-4.54M
2024Q3
633
93.51M
101.49%
-6.93M
2024Q2
618
95.17M
101.90%
+3.05M
2024Q1
605
86.17M
101.67%
-4.74M
2023Q4
588
86.44M
105.27%
+5.64M
2023Q3
574
75.90M
106.07%
-3.60M
2023Q2
591
75.05M
105.07%
-3.13M
2023Q1
609
74.12M
105.56%
-2.85M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
9.98M
10.55%
-38.64K
-0.39%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
4.91M
5.2%
-49.62K
-1.00%
Mar 31, 2025
Sands Capital Management, LLC
4.16M
4.4%
-134.44K
-3.13%
Mar 31, 2025
T. Rowe Price Associates, Inc.
3.14M
3.32%
+698.80K
+28.65%
Mar 31, 2025
Kakkis (Emil D)
2.69M
2.85%
-31.78K
-1.17%
Mar 07, 2025
State Street Global Advisors (US)
2.62M
2.77%
-104.13K
-3.82%
Mar 31, 2025
Wellington Management Company, LLP
2.45M
2.59%
-8.04K
-0.33%
Mar 31, 2025
ClearBridge Investments, LLC
2.26M
2.39%
-62.50K
-2.69%
Mar 31, 2025
Adage Capital Management, L.P.
2.15M
2.27%
+965.92K
+81.64%
Mar 31, 2025
Federated Hermes Global Investment Management Corp.
2.05M
2.17%
+3.00K
+0.15%
Mar 31, 2025
查看更多
持股ETF
更新时间: 7月6日 周日
更新时间: 7月6日 周日
机构名称
占比
Global X Genomics & Biotechnology ETF
3.89%
Motley Fool Small-Cap Growth ETF
3%
Motley Fool Mid-Cap Growth ETF
2.01%
Franklin Genomic Advancements ETF
2%
Virtus LifeSci Biotech Products ETF
1.84%
Touchstone Sands Capital US Select Growth ETF
1.26%
WisdomTree BioRevolution Fund
1.12%
SPDR S&P Biotech ETF
0.77%
Putnam Sustainable Future ETF
0.63%
Goldman Sachs Future Health Care Equity ETF
0.6%
查看更多
Global X Genomics & Biotechnology ETF
占比3.89%
Motley Fool Small-Cap Growth ETF
占比3%
Motley Fool Mid-Cap Growth ETF
占比2.01%
Franklin Genomic Advancements ETF
占比2%
Virtus LifeSci Biotech Products ETF
占比1.84%
Touchstone Sands Capital US Select Growth ETF
占比1.26%
WisdomTree BioRevolution Fund
占比1.12%
SPDR S&P Biotech ETF
占比0.77%
Putnam Sustainable Future ETF
占比0.63%
Goldman Sachs Future Health Care Equity ETF
占比0.6%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
